University of Nebraska
Grant in 2024
The official LinkedIn page for the University of Nebraska, the only public research university in the state of Nebraska.
University of Nebraska-Lincoln
Grant in 2024
The largest university in the state, the University of Nebraska at Lincoln offers academic programs and research that have long placed it at the forefront of education. For example, University of Nebraska is one of the first universities to establish a major in Digital Humanities, offered through the English Department. In the same department, graduate students may undertake UNL’s prestigious MFA program in Creative Writing, which has leading writers among its faculty and is also responsible for founding one of the country’s most respected university literary publications. On the fine arts end of things, UNL boasts top museums and galleries with collections by some of the world’s most revered artists. UNL also has a natural history museum, which features fossils and other types of ancient excavations. Additional areas of study include: *Agricultural Sciences *Architecture *Education *Engineering *Law *Liberal Arts and Humanities *Performing Arts *Mass Communications UNL has long been distinguished for its research activity as well, conducting valuable research in a variety of scientific and other fields.
Bigfoot Biomedical
Acquisition in 2023
Bigfoot Biomedical, Inc. is a medical device company focused on transforming diabetes care for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company specializes in developing an integrated diabetes management system that features cloud connectivity and human-centered automation. This system optimizes insulin dosing and delivery through a combination of automated infusion pumps and connected insulin pen options. Bigfoot Biomedical's innovative approach employs machine learning and user-friendly technologies to alleviate the cognitive, emotional, and financial burdens associated with insulin-requiring diabetes. By offering a comprehensive digital drug delivery platform through a unique monthly subscription service model, the company aims to enhance the quality of life for patients managing their diabetes.
Cardiovascular Systems
Acquisition in 2023
Cardiovascular Systems, Inc., established in 1989, specializes in developing and marketing innovative medical technologies for treating peripheral and coronary artery diseases. The company's primary product line is its orbital atherectomy systems, which employ a diamond-coated crown to remove plaque from arteries above and below the knee. These catheter-based platforms are designed to tackle challenging disease states, including calcium buildup, which is particularly prevalent in peripheral artery disease (PAD) and coronary artery disease (CAD). Cardiovascular Systems generates most of its revenue through sales of these peripheral orbital atherectomy systems in the United States.
Easterseals is a nonprofit organization dedicated to ensuring that children and adults with disabilities have equal opportunities to live, learn, work, and play. Founded in 1944, the organization continuously develops innovative programs to meet the specific needs of its clients. Easterseals offers a wide range of services, including physical, occupational, and speech therapy, assistive technology support, and job training and employment assistance. It provides developmental therapy services for individuals with disabilities, as well as summer camping programs that enrich the lives of children with disabilities. Additionally, Easterseals facilitates community outreach, social services, and advocates for the needs of people with disabilities at local and national levels. With a commitment to expanding independence, Easterseals enhances the quality of life for individuals and families through its diverse programs and resources.
Howard University
Grant in 2021
Howard University, located in Washington, D.C., is an esteemed institution established in 1867 that focuses on providing educational opportunities, particularly for African-American students. The university offers a wide range of academic programs at the undergraduate, graduate, and doctoral levels, including fields such as law, medicine, and pharmaceutical studies. With a commitment to fostering high academic achievement and potential, Howard University aims to enhance the educational landscape while reflecting the political and cultural dynamics of its environment.
Walk Vascular
Acquisition in 2021
Walk Vascular is a commercial-stage medical device company focused on developing innovative solutions for patients with peripheral arterial and venous diseases. The company specializes in a minimally invasive mechanical aspiration thrombectomy system designed to effectively remove blood clots from the peripheral vasculature. This system not only addresses the removal of soft emboli and thrombus but also facilitates the infusion and delivery of diagnostics or therapeutics, enhancing patient care without the need for vessel occlusion. Walk Vascular aims to improve treatment outcomes and the quality of life for individuals affected by these conditions.
Bigfoot Biomedical
Series C in 2020
Bigfoot Biomedical, Inc. is a medical device company focused on transforming diabetes care for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company specializes in developing an integrated diabetes management system that features cloud connectivity and human-centered automation. This system optimizes insulin dosing and delivery through a combination of automated infusion pumps and connected insulin pen options. Bigfoot Biomedical's innovative approach employs machine learning and user-friendly technologies to alleviate the cognitive, emotional, and financial burdens associated with insulin-requiring diabetes. By offering a comprehensive digital drug delivery platform through a unique monthly subscription service model, the company aims to enhance the quality of life for patients managing their diabetes.
Cephea Valve Technologies
Acquisition in 2019
Cephea Valve Technologies, Inc. is a medical device company based in San Jose, California, specializing in catheter-delivered solutions for mitral valve regurgitation and coronary artery disease. Founded in 2011, the company develops innovative technologies that facilitate the replacement of mitral valves through minimally invasive procedures. This approach involves delivering an artificial valve via a vein in the leg, eliminating the need for traditional open-heart surgery. By focusing on catheter-based therapies, including balloons and stents for aortic valve replacements, Cephea aims to enhance treatment options for patients suffering from mitral valve disease.
Alere Inc., formerly known as Inverness Medical Innovations, is a company that specializes in diagnostics and health management solutions. It focuses on infectious disease, cardiology, oncology, drugs of abuse, and women's health, offering a wide array of products and services. Alere's portfolio includes over-the-counter tests, lab-based diagnostics, and integrated home monitoring solutions, with notable brands such as Acceava Mono cassette, Alere Home Monitoring, AtheNA Multi-Lyte Test System, and BinaxNOW. The company operates across multiple regions, including North America, Europe, the Middle East, Asia Pacific, and Latin America and Africa. Its medical diagnostic products aim to facilitate the detection of diseases and conditions, empowering patients and healthcare providers to collaboratively manage health outcomes throughout the continuum of care from hospitals to home settings.
St. Jude Medical
Acquisition in 2016
St. Jude Medical is a global company based in St. Paul, Minn., that specializes in developing medical technology and services for cardiac, neurological, and chronic pain patients. With a workforce of over 14,000 employees worldwide, the company focuses on providing innovative solutions in cardiac rhythm management, atrial fibrillation, cardiovascular, and neuromodulation. Their product portfolio includes a range of devices such as implantable cardioverter defibrillators, pacemakers, heart valve replacement products, and neurostimulation devices. St. Jude Medical aims to empower healthcare professionals with tools that enhance patient care, reduce risks, and improve treatment outcomes across the globe.
Kalila Medical
Acquisition in 2016
Kalila Medical specializes in developing advanced catheter technologies focused on vascular and intracardiac access. Founded in 2010, the company offers a platform of specialized delivery and access catheters, with a primary product line that includes steerable sheaths designed for catheter-based atrial fibrillation ablation. These sheaths, compatible with various ablation catheters, enhance precision by providing superior torque and tip control during catheter delivery and lesion formation. Additionally, Kalila Medical's technologies are applicable across a range of endovascular procedures, including mitral valve repair, ASD/PFO closure, left atrial appendage closure, transseptal puncture, and LV lead placement. The company is part of a portfolio formed from Shifamed LLC, a Silicon Valley-based medical device incubator.
Alere Inc., formerly known as Inverness Medical Innovations, is a company that specializes in diagnostics and health management solutions. It focuses on infectious disease, cardiology, oncology, drugs of abuse, and women's health, offering a wide array of products and services. Alere's portfolio includes over-the-counter tests, lab-based diagnostics, and integrated home monitoring solutions, with notable brands such as Acceava Mono cassette, Alere Home Monitoring, AtheNA Multi-Lyte Test System, and BinaxNOW. The company operates across multiple regions, including North America, Europe, the Middle East, Asia Pacific, and Latin America and Africa. Its medical diagnostic products aim to facilitate the detection of diseases and conditions, empowering patients and healthcare providers to collaboratively manage health outcomes throughout the continuum of care from hospitals to home settings.
SetPoint Medical
Series C in 2015
SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for the treatment of debilitating inflammatory diseases. Established in 2006 and formerly known as Innovative Metabolics Inc., the company aims to provide innovative solutions for chronic autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease. SetPoint Medical's technology leverages vagus nerve stimulation to activate the body's natural inflammatory reflex, producing a systemic anti-inflammatory effect. This platform offers an alternative treatment option that may present lower risks and costs compared to traditional drug therapies, ultimately seeking to improve patient outcomes in managing chronic inflammatory diseases.
Tendyne Holdings
Acquisition in 2015
Tendyne Holdings Inc. is a clinical stage medical device company based in Roseville, Minnesota, and was incorporated in 2010. The company specializes in the development of innovative minimally invasive therapies for mitral regurgitation, a condition affecting numerous individuals globally. Tendyne Holdings focuses on creating a transcatheter mitral valve replacement prosthesis designed to treat this affliction. The valve is engineered to be deployed and secured without disrupting the native mitral annulus, while preserving the sub-valvular apparatus. The placement procedure is intended to be simple and performed transapically, allowing the implanting physician to reposition, remove, and re-deploy the valve as necessary during the intervention. In August 2015, Tendyne Holdings became a subsidiary of Abbott Laboratories.
Veropharm
Acquisition in 2014
Veropharm is a prominent Russian pharmaceutical manufacturer founded in 1997, known for producing generic drugs, oncological medications, and medical adhesive bandages. The company operates three production facilities located in Voronezh, Belgorod, and Pokrov, with a combined annual production capacity of 591 million tablets and capsules, 7 million ampoules, 468 million adhesive bandages, and 43 million vials. Veropharm offers approximately 240 different medical products across 12 anatomical and therapeutic groups, specializing in areas such as oncology, women's health, gastroenterology, infectious diseases, dermatology, and neurology. The company is recognized both in Russia and internationally, contributing significantly to the pharmaceutical market. As of September 2013, Veropharm operates as a subsidiary of GardenHills OOO.
Topera
Acquisition in 2014
Topera Medical is a venture-backed medical device company focused on enhancing the diagnosis and treatment of complex cardiac arrhythmias. It has developed an innovative 3D analysis and mapping system that assists electrophysiologists in identifying the electrical sources of these arrhythmias. The Topera System comprises the RhythmView Workstation and the FIRMap diagnostic catheter, which together offer a dynamic representation of the heart's electrical activity. This technology supports the diagnosis and treatment planning for various arrhythmias, including atrial fibrillation, atrial flutter, atrial tachycardia, and ventricular tachycardia, ultimately aiming to improve patient outcomes.
CFR Pharmaceuticals
Acquisition in 2014
CFR Pharmaceuticals is a prominent multinational pharmaceutical company operating in 15 Latin American countries, including Chile, Peru, Argentina, and Colombia, as well as other emerging markets. The company specializes in the development, manufacture, and commercialization of branded generics and complex injectables. Its diverse portfolio includes therapeutic products in various fields such as neurology, psychiatry, cardiology, women’s health, and respiratory diseases. Key business segments include Drugtech, which focuses on neurology and cardiology; Gynopharm, dedicated to women's health; Recalcine, targeting acute therapeutic areas; and Biomedical Sciences, which involves monoclonal antibodies and treatments for oncology and rheumatology. Additionally, CFR Pharmaceuticals offers complex injectables for critical care and various sterile applications, underscoring its commitment to addressing a wide range of healthcare needs.
UNeLAB
Acquisition in 2014
UNeLAB develops technology for the automation of laboratory processes and services.
IDev Technologies
Acquisition in 2013
IDEV Technologies is an emerging growth medical device company that specializes in the development of innovative products for endovascular and interventional applications, particularly within interventional radiology, gastroenterology, vascular surgery, and cardiology. The company markets its flagship product, SUPERA, a self-expanding nitinol stent designed with a patented interwoven structure that enhances flexibility, radial strength, and resistance to kinking and crushing compared to competing stents. SUPERA is approved for treating biliary strictures in the United States and is currently undergoing clinical evaluation in the SUPERB IDE trial to assess its safety and efficacy for use in the superficial femoral artery.
OptiMedica
Acquisition in 2013
OptiMedica Corporation is a Silicon Valley-based ophthalmic device company established in 2004, focused on advancing technologies to enhance patient outcomes in eye care. The company specializes in developing a noninvasive, reproducible technique that utilizes femtosecond laser technology to improve the precision and consistency of cataract surgery, addressing the limitations of traditional manual methods. OptiMedica's flagship product, the Catalys Precision Laser System, has undergone successful clinical trials, demonstrating significant improvements in performance and efficacy for cataract surgeons and their patients. Although the system is not yet available for sale in the United States, OptiMedica aims to launch it in both U.S. and international markets.
Respicardia
Series C in 2010
Respicardia, Inc. is a medical technology company based in Minnetonka, Minnesota, focused on enhancing respiratory rhythm management and cardiovascular health for heart failure patients. Founded in 2006, the company develops and manufactures innovative implantable stimulation therapy solutions, notably the remede System. This device is designed to restore normal breathing patterns during sleep for individuals suffering from central sleep apnea. Respicardia aims to improve the lives of these patients through safe and effective neurostimulation therapies that stimulate the phrenic nerve, thereby addressing critical needs in respiratory and cardiovascular health.
Piramal Healthcare Solutions
Acquisition in 2010
Piramal Healthcare Solutions provides pharma and health care services.
Facet Biotech
Acquisition in 2010
Facet Biotech Corporation is a biotechnology company based in Redwood City, California, focused on the identification and development of oncology drugs. Formed as a spin-off from the biotechnology segment of PDL BioPharma in December 2008 and later acquired by Abbott Laboratories, Facet Biotech is advancing several therapeutic products. These include Daclizumab, a monoclonal antibody in Phase IIb clinical studies for targeting activated T cells, and Volociximab, which is in Phase I studies to inhibit proteins in activated endothelial cells. The company is also developing Elotuzumab, a monoclonal antibody for myeloma treatment, along with other candidates like PDL192 and PDL241, which target various pathways involved in cancer and autoimmune diseases. Additionally, TRU-016 is being investigated as a potential treatment for B-cell malignancies. Facet Biotech has formed collaborations and licensing agreements with notable pharmaceutical companies to further its research and development efforts.
STARLIMS
Acquisition in 2009
STARLIMS provides Laboratory Information Management Software (LIMS) to help laboratories optimize data management, accessibility, integrity and long-term value.
PanGenetics
Acquisition in 2009
PanGenetics B.V., based in Utrecht, Netherlands, specializes in the development of monoclonal antibodies aimed at treating immune-mediated diseases. The company focuses on advancing antibodies from late-stage research to clinical proof of concept, utilizing a lean business model that outsources manufacturing and clinical development to specialized providers. Among its clinical programs is PG110, along with PG102, a CD40 antagonist currently undergoing evaluation in a clinical study for patients with psoriatic arthritis. Additionally, PanGenetics employs an in-licensing model to expand its portfolio of antibody-based therapeutic products. The company's strategic approach allows it to concentrate on its core competencies while leveraging external expertise for other critical functions.
Solvay Pharmaceuticals
Acquisition in 2009
Solvay Pharmaceuticals B.V. operates as a pharmaceutical and drugs company. The company is based in Weesp, the Netherlands. Solvay Pharmaceuticals operated as a subsidiary of [Solvay SA](/organization/solvay) until it was acquired by [Abbott Labs](/organization/abbott) in 2009.
Evalve
Acquisition in 2009
Evalve, Inc. engages in the design, development, manufacture, and marketing of devices that enable the repair of cardiac valves. It provides a non-surgical mitral valve repair system consisting of a steerable guide catheter, a clip delivery system, and an implant device that is used by interventional cardiologists to reduce mitral regurgitation. The company was incorporated in 1999 and is based in Menlo Park, California.
Visiogen
Acquisition in 2009
Visiogen, Inc. is an ophthalmic medical device company focused on creating innovative vision solutions for cataract patients, including those with presbyopia. The company's flagship product is the Synchrony dual optic accommodating intraocular lens (IOL), designed to deliver a seamless vision experience across near, intermediate, and distance ranges without the need for corrective eyewear. To enhance surgical efficiency, the Synchrony IOL is supplied in a pre-loaded injector, minimizing lens handling during procedures. This advanced technology has received CE Mark approval in Europe and is currently undergoing clinical trials in the United States, reflecting Visiogen's commitment to improving patient outcomes in cataract surgery.
Abbott
Acquisition in 2009
Abbott, established in 1910, is a global healthcare company with a diverse portfolio of products. It is a leader in pharmaceuticals, with notable brands like Norvir (HIV treatment), Synthroid (synthetic thyroid hormone), and Humira (rheumatoid arthritis drug). In diagnostics, Abbott Molecular specializes in molecular diagnostics, offering over 350 products for infectious disease, oncology, and genetics. Abbott's medical devices division is prominent in cardiovascular and diabetes care, with products such as pacemakers, glucose monitors, and neuromodulation devices. Additionally, Abbott is a significant player in eye care, ranking first in LASIK and second in cataract surgery with its TECNIS platform. The company's nutritional division provides a range of products for both adults and infants. Abbott India, a subsidiary, focuses on women's health, gastroenterology, and metabolic disorders. Approximately 60% of Abbott's sales come from outside the United States.
Ibis Biosciences
Acquisition in 2008
Ibis Biosciences, Inc. is a biotechnology company focused on developing, manufacturing, and marketing systems for the identification and characterization of infectious agents. Its flagship product, the Ibis T5000 Biosensor System, is a hardware platform designed to detect biological organisms, including bacteria, viruses, fungi, and protozoa, and to provide critical information on drug resistance, virulence, and strain type. In addition to the biosensor system, Ibis Biosciences offers various assay kits and panels for strain genotyping and characterization, alongside essential consumables such as plates, buffers, and reagents for PCR. The company also provides specialized assay services, including human forensics, mitochondrial DNA assays, and bacterial and viral detection and profiling. These products and services are utilized across multiple applications, including clinical research, healthcare-associated infection monitoring, and forensic analysis. Incorporated in 2006 and based in Carlsbad, California, Ibis Biosciences operates as a subsidiary of Abbott Molecular Inc.
Evalve, Inc. engages in the design, development, manufacture, and marketing of devices that enable the repair of cardiac valves. It provides a non-surgical mitral valve repair system consisting of a steerable guide catheter, a clip delivery system, and an implant device that is used by interventional cardiologists to reduce mitral regurgitation. The company was incorporated in 1999 and is based in Menlo Park, California.
Nova Science
Acquisition in 2007
Nova Science was established in 1999 by Jim Coleman, the previous founder of Chiroxia. Mr. Coleman, a vascular surgeon, has been a senior medical director of various multinational firms including Tyco.
IntraLase
Acquisition in 2007
IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.
Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.
KOS Pharmaceuticals
Acquisition in 2006
KOS Pharmaceuticals manufactures prescription products for the treatment of chronic cardiovascular diseases. Their products are used treatment of primary hypercholesterolemia and mixed dyslipidemia, mixed lipid disorders, and non dihydropyridine calcium channel blocker, enabling doctors to treat hypertension and chronic stable angina.
Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.
Spine Next
Acquisition in 2004
Spine Next is a France-based biotech company established in 1999, specializing in the manufacture and marketing of orthopedic spinal implant devices designed for spinal fusion surgeries. The company is known for its Wallis system, a stabilization device that addresses degenerative disc disease without the need for vertebral fusion. In 2004, Spine Next was acquired by Abbott, further enhancing its capabilities in the orthopedic market.
Experimental and Applied Sciences (EAS) is a manufacturer and provider of nutritional supplements designed to enhance health and fitness. The company offers a diverse range of over 70 active nutrition products, including ready-to-drink shakes, powders, energy bars, low-carbohydrate snacks, thermogenic beverages, and various sports nutrition items. EAS markets its products directly to consumers as well as through mass merchandisers and specialty retailers, ensuring broad accessibility for individuals seeking to improve their nutritional intake and overall wellness.
TheraSense
Acquisition in 2004
TheraSense develop and sell easy to use glucose self-monitoring systems for peoplewith diabetes that dramatically reduce the pain of testing. Using ourproprietary technologies, we have developed products that are less painful touse than current products on the market. FreeStyle, our first product, canaccurately measure glucose levels in a blood sample that is a fraction of thesample size required by other systems. This small sample requirement enablesusers to obtain the sample from their forearms, and thereby dramaticallyreduces the pain and inconvenience associated with a larger blood sample takenfrom their fingertips.
i-STAT Corp.
Acquisition in 2004
i-STAT Corporation develops, manufactures and markets diagnostic products for blood analysis that provide health care professionals critical diagnostics information accurately and immediately at the point of patient care.
Hydra Biosciences
Series B in 2004
Hydra Biosciences, headquartered in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to developing innovative drugs targeting pain, inflammation, and cardiovascular diseases. The company leverages its expertise in novel ion channels and proprietary high-throughput screening platforms to identify and advance drug candidates addressing substantial unmet medical needs. Hydra's focus lies in TRP ion channels, offering potential for selective and safer therapies compared to classical voltage-gated channels. Since its founding, Hydra has secured significant funding from prominent investors such as Abingworth Ventures, Advanced Technology Ventures, and New Enterprise Associates, among others.
Integrated Vascular Systems
Acquisition in 2003
Integrated Vascular Systems, Inc. designs, manufactures, and develops blood vessel closure devices for the healthcare industry. The company's products allow closure of femoral artery incisions during surgical procedures.
ZonePerfect Nutrition Company
Acquisition in 2003
ZonePerfect Nutrition Company specializes in the development and marketing of nutrition bars and related products aimed at improving health and immunity. The company's offerings include a variety of flavors such as classic, dark chocolate, cookie dough, and sweet and salty, catering to diverse consumer preferences. ZonePerfect's products are formulated to adhere to a balanced 40/30/30 ratio of carbohydrates, protein, and dietary fat, positioning the brand within the expanding sectors of healthy living and weight management. These products are distributed through major food, drug, and mass merchandising channels across the United States, as well as through a direct-to-consumer program, ensuring accessibility for health-conscious consumers.
Woodside Biomedical (acquired by Abbott Laboratories)
Acquisition in 2003
Manufactures and distributes medical device which is used to provide relief for nausea and vomitting from various causes.
Spinal Concepts
Acquisition in 2003
Spinal Concepts is a biotechnology company focused on spinal fixation products used in the treatment of spinal disorders, diseases, and injuries. The company was founded by Erin McGurk in 1996.
Vysis is a genomic disease management company that develops, commercializes, and markets clinical products aimed at providing critical information for the evaluation and management of cancer, prenatal disorders, and other genetic diseases. The company is recognized for its pioneering role in obtaining FDA clearance for genomic products using fluorescence in situ hybridization (FISH). Vysis markets four FDA-cleared clinical products and distributes over 240 research products through its direct sales operations in the United States and Europe, supported by a worldwide distribution network encompassing 28 countries. The company has established a significant presence with over 320 proprietary genetic workstations installed in 224 laboratories across 18 countries. Additionally, Vysis has a robust pipeline of nine clinical products under development and continues to expand its offerings through collaborations with prominent medical research institutions, including the University of California, San Francisco, the Mayo Clinic, and St. Jude Children's Research Hospital.
Abbott
Acquisition in 2000
Abbott, established in 1910, is a global healthcare company with a diverse portfolio of products. It is a leader in pharmaceuticals, with notable brands like Norvir (HIV treatment), Synthroid (synthetic thyroid hormone), and Humira (rheumatoid arthritis drug). In diagnostics, Abbott Molecular specializes in molecular diagnostics, offering over 350 products for infectious disease, oncology, and genetics. Abbott's medical devices division is prominent in cardiovascular and diabetes care, with products such as pacemakers, glucose monitors, and neuromodulation devices. Additionally, Abbott is a significant player in eye care, ranking first in LASIK and second in cataract surgery with its TECNIS platform. The company's nutritional division provides a range of products for both adults and infants. Abbott India, a subsidiary, focuses on women's health, gastroenterology, and metabolic disorders. Approximately 60% of Abbott's sales come from outside the United States.
Glaxo Wellcome - Anesthesia Business
Acquisition in 1999
Glaxo Wellcome - Anesthesia Business Included in the acquisition are four neuromuscular blockers (muscle relaxants) and Ultiva ® ; (remifentanil ), an ultra-short acting analgesic.
Perclose
Acquisition in 1999
Perclose, Inc. designs, develops, manufactures, and markets a family of medical devices that automate the surgical closure or connection of blood vessels. It offers Perclose percutaneous vascular surgery devices, which surgically close the arterial access site in the femoral artery after catheterization procedures, such as angioplasty, stenting, atherectomy, and diagnostic angiography; and Heartflo Anastomosis System, which allows cardiac surgeons to automate the rapid placement of sutures in blood vessels during coronary artery bypass graft surgery.
ALZA Corp.
Acquisition in 1999
ALZA Corp. is a pharmaceutical and medical systems company that develops, manufactures, and markets therapeutic systems. It provides oral, transdermal, implantable, and liposomal technologies. It is also focused on drug delivery systems with over 20 prescription pharmaceutical products. With over 10,000 employees, ALZA Corp. is a subsidiary of Johnson & Johnson. It was established in 1968 by Dr Alejandro Zaffaroni. It is based inVacaville, California.
International Murex Technologies
Acquisition in 1998
Murex develops, manufactures and markets a wide range of products for the detection, screening and monitoring of infectious diseases and other medical conditions.
Sanofi - Parenteral Products Businesses
Acquisition in 1997
Sanofi - Parenteral Products Businesses makes pre-filled, single-dose syringe technology.
MediSense
Acquisition in 1996
MediSense, Inc. was engaged in the development, manufacture, and marketing of self-testing blood glucose monitoring systems that enabled people with diabetes to manage their disease effectively.
Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on innovative and long-term implantable glucose monitoring solutions that utilize advanced fluorescence sensing technology. Its flagship products, Eversense and Eversense XL, are implantable CGM systems designed to monitor glucose levels for up to 90 and 180 days, respectively. These products aim to provide users with a reliable and stable means of glucose management, enhancing their ability to live confidently and manage their diabetes effectively. The majority of Senseonics' revenue comes from international markets, reflecting its strong presence in Europe.